image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - CA
$ 4.54
1.57 %
$ 255 M
Market Cap
23.89
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ACB stock under the worst case scenario is HIDDEN Compared to the current market price of 4.54 USD, Aurora Cannabis Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ACB stock under the base case scenario is HIDDEN Compared to the current market price of 4.54 USD, Aurora Cannabis Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ACB stock under the best case scenario is HIDDEN Compared to the current market price of 4.54 USD, Aurora Cannabis Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ACB

image
$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
343 M REVENUE
27.01%
4.95 M OPERATING INCOME
110.65%
15.8 M NET INCOME
126.70%
16 M OPERATING CASH FLOW
123.36%
-14.3 M INVESTING CASH FLOW
-161.11%
-116 K FINANCING CASH FLOW
99.76%
90.5 M REVENUE
2.65%
-30.4 M OPERATING INCOME
-82.46%
-22 M NET INCOME
-70.40%
3.68 M OPERATING CASH FLOW
-87.23%
-8.29 M INVESTING CASH FLOW
-158.13%
8.7 M FINANCING CASH FLOW
256.07%
Balance Sheet Aurora Cannabis Inc.
image
Current Assets 478 M
Cash & Short-Term Investments 138 M
Receivables 42.5 M
Other Current Assets 297 M
Non-Current Assets 374 M
Long-Term Investments 0
PP&E 268 M
Other Non-Current Assets 106 M
16.24 %4.98 %34.88 %31.44 %12.46 %Total Assets$852.7m
Current Liabilities 111 M
Accounts Payable 27.6 M
Short-Term Debt 26.9 M
Other Current Liabilities 56.3 M
Non-Current Liabilities 133 M
Long-Term Debt 77.7 M
Other Non-Current Liabilities 55.5 M
11.32 %11.02 %23.09 %31.83 %22.75 %Total Liabilities$244.1m
EFFICIENCY
Earnings Waterfall Aurora Cannabis Inc.
image
Revenue 343 M
Cost Of Revenue 156 M
Gross Profit 188 M
Operating Expenses 183 M
Operating Income 4.95 M
Other Expenses -10.8 M
Net Income 15.8 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00343m(156m)188m(183m)5m11m16mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
54.65% GROSS MARGIN
54.65%
1.44% OPERATING MARGIN
1.44%
0.46% NET MARGIN
0.46%
0.28% ROE
0.28%
0.19% ROA
0.19%
0.50% ROIC
0.50%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Aurora Cannabis Inc.
image
00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)(700m)(700m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 15.8 M
Depreciation & Amortization 22.5 M
Capital Expenditures -18.9 M
Stock-Based Compensation 11.5 M
Change in Working Capital 10.2 M
Others -35.7 M
Free Cash Flow -2.85 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Aurora Cannabis Inc.
image
Wall Street analysts predict an average 1-year price target for ACB of $6.67 , with forecasts ranging from a low of $1 to a high of $11 .
ACB Lowest Price Target Wall Street Target
1 USD -77.97%
ACB Average Price Target Wall Street Target
6.67 USD 46.84%
ACB Highest Price Target Wall Street Target
11 USD 142.29%
Price
Max Price Target
Min Price Target
Average Price Target
11111010998877665544332211Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Aurora Cannabis Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Americans Should Buy Canadian Cannabis Companies Canadian LPs offer compelling risk/reward versus U.S. cannabis stocks, with stronger balance sheets, tangible book value, and global opportunities due to federal legality. Despite recent rallies, Canadian LPs remain cheap on enterprise value to EBITDA, especially Village Farms, Organigram, and Tilray Brands, which I hold in my model portfolio. U.S. MSOs face significant risks from 280E tax liabilities and negative tangible equity, making Canadian LPs a safer bet for cannabis investors right now. seekingalpha.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aurora Cannabis Inc. - ACB NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aurora Cannabis Inc.  ("Aurora Cannabis" or the "Company") (NASDAQ: ACB).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aurora Cannabis Inc. - ACB NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aurora Cannabis Inc. ("Aurora Cannabis" or the "Company") (NASDAQ: ACB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aurora Cannabis Inc. - ACB NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aurora Cannabis Inc.  ("Aurora Cannabis" or the "Company") (NASDAQ: ACB).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 weeks ago
Aurora Expands Patient Access to Medical Cannabis in Canada with Extended Compassionate Pricing Program Canada's Largest Medical Cannabis Company Offers the Country's Most Inclusive Medical Cannabis Pricing Program NASDAQ | TSX: ACB EDMONTON, AB , June 26, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to have recently expanded eligibility of their medical compassionate pricing program in Canada. As part of the company's ongoing commitment to making medical cannabis more accessible to patients, the yearly income eligibility of the program has increased from $40,000 to $60,000 CAD for Aurora patients through AuroraMedical.com. prnewswire.com - 2 weeks ago
Aurora Sets New Standard in Poland with the Launch of Two High Potency Flower Products Proprietary Genetics to be the Highest Potency Medical Cannabis Products Available on the Market NASDAQ | TSX: ACB EDMONTON, AB , June 24, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces today the launch of two new proprietary cultivars in Poland, marking the highest potency medical cannabis products available in the country. Grown and manufactured in the company's Canadian GACP and EU-GMP facilities, the premium dried medical cannabis products Farm Gas and Sourdough are crafted with precision and expertise to deliver a superior, high THC flower. prnewswire.com - 2 weeks ago
Aurora Cannabis Falls On Weak 2026 Outlook Despite Record Q4 Revenues Aurora Cannabis recently reported improved Q4-2025 results. ACB's international medical cannabis sales are increasing revenues. The company reported record revenues, but low gross profit and weak 2026 outlook. seekingalpha.com - 3 weeks ago
3 Cannabis Stocks For Investors To Secure For Future Gains The current state of the cannabis sector has people feeling a type of way. To be more descriptive, those who are invested in marijuana stocks are feeling the backlash of the market. For some time, there has been a sharp decline in the overall trading for most top marijuana stocks. Now, you would think that with the sector down and showing no true signs of recovery, all is lost. That is not the case, as most companies are making money and having a positive impact. marijuanastocks.com - 3 weeks ago
Aurora Cannabis Advises of Second False Article from Investing.com NASDAQ | TSX: ACB EDMONTON, AB , June 19, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has become aware of a second instance of misinformation posted on news website, Investing.com.  On June 18, 2025, Aurora advised the market that an article posted on Investing.com incorrectly stated that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics. prnewswire.com - 3 weeks ago
Aurora Cannabis Denies News of Acquisition of MedLeaf Therapeutics NASDAQ | TSX: ACB EDMONTON, AB , June 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has become aware of misinformation posted on a news website, incorrectly stating that Aurora has agreed to acquire New Zealand based MedLeaf Therapeutics. The Company has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics with respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction. prnewswire.com - 3 weeks ago
Aurora Cannabis: Poland Headwinds Result In Disappointing Outlook (Rating Downgrade) Aurora Cannabis reported mixed Q4/FY2025 results, with higher-than-expected revenues offset by lower profitability due to a number of one-time expenses. Following substantial growth in recent quarters, medical cannabis sales were essentially flat on a quarter-over-quarter basis. On the conference call, management admitted to headwinds from recent regulatory changes in Poland. As a result, medical cannabis sales and profitability are expected to decline in Q1/FY2026. seekingalpha.com - 3 weeks ago
Aurora Cannabis Inc. (ACB) Q4 2025 Earnings Call Transcript Aurora Cannabis Inc. (NASDAQ:ACB ) Q4 2025 Earnings Conference Call June 18, 2025 8:00 AM ET Company Participants Kevin Niland - Corporate Participant Miguel Martin - CEO & Executive Chairman Simona King - Chief Financial Officer Conference Call Participants Derek J. Lessard - TD Cowen, Research Division Frederico Yokota Choucair Gomes - ATB Capital Markets Inc., Research Division Matt Bottomley - Canaccord Genuity Corp., Research Division Pablo Ernesto Zuanic - Zuanic & Associates William Joseph Kirk - ROTH Capital Partners, LLC, Research Division Operator Greetings. seekingalpha.com - 3 weeks ago
8. Profile Summary

Aurora Cannabis Inc. ACB

image
COUNTRY CA
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 255 M
Dividend Yield 0.00%
Description Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Contact 500 - 10355 Jasper Avenue, Edmonton, AB, T5J 1Y6 https://www.auroramj.com
IPO Date July 15, 2014
Employees 1073
Officers Michelle Lefler Vice President of Communications & Public Relations Mr. Ananth Krishnan Vice President of Capital Markets & Investor Relations Ms. Simona King CPA Chief Financial Officer Mr. Alex Miller Executive Vice President of Operations & Supply Chain Mr. Rick Savone Senior Vice President of Global Government Relations Ms. Nathalie Clark Executive Vice President, General Counsel & Corporate Secretary Dr. Jonathan Page Ph.D. Senior Science Advisor Mr. Andre Jerome Executive Vice President of Global Business Development Ms. Lori Schick Executive Vice President of Human Resources Mr. Miguel Martin Chief Executive Officer & Executive Chairman